Clinical TrialJun 4, 2026, 04:06 PM
Lyell Immunopharma to Present Ronde-cel Data at EHA 2026 Congress
AI Summary
Lyell Immunopharma announced it will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) at the European Hematology Association (EHA) 2026 Congress. The presentations will feature an updated safety analysis and translational insights for ronde-cel in patients with relapsed or refractory large B-cell lymphoma. The company expects updated data from its PiNACLE trial in the second half of 2026, pivotal data by mid-2027, and a Biologics License Application submission in 2027.
Key Highlights
- Lyell Immunopharma to present Phase 1/2 clinical trial data for ronde-cel at EHA 2026 Congress.
- Presentations will cover updated safety analysis and translational insights for ronde-cel.
- Ronde-cel is being evaluated for relapsed or refractory large B-cell lymphoma (R/R LBCL).
- PiNACLE trial (3L+ setting) expects updated data in H2 2026 and pivotal data by mid-2027.
- Biologics License Application (BLA) submission for ronde-cel is anticipated in 2027.
- PiNACLE-H2H trial (2L setting) compares ronde-cel against axicabtagene ciloleucel or lisocabtagene maraleucel.
Price Impact
More from LYEL